header

Publikationen

Prof. Dr. Bernd Joachim Krause

Prof. B. J. Krause

Originalarbeiten in wissenschaftlichen Fachzeitschriften 2011-2018

Stand: August 2018

2018

 

Nuklearmedizin in Deutschland

Krause BJ

Nuklearmedizin 2018;57(3):66-67

 

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

Roolf C, Richter A, Konkolefski C, Knuebel G, Sekora A, Krohn S, Stenzel J, Krause BJ, Vollmar B, Murua Escobar H, Lunghanns C

J Hematol Oncol 2018;11:62

 

External radiation exposure, excretion, and effective half-live in 177Lu-PSMA-targeted therapies

Kurth J, Krause BJ, Schwarzenböck SM, Stegger L, Schäfers M, Rahbar K

EJNMMI Res. 2018;8:32

 

Somatostatin receptor PET/CT (SSTR-PET/CT)

Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A

Nuklearmedizin 2018;57(1):4-17

 

[18F]fallypride-PET/CT Analysis of the Dopamine D/D Receptor in the Hemiparkinsonian Rat Brain Following Intrastriatal Botulinum Neurotoxin A Injection.

Mann T, Kurth J, Hawlitschka A, Stenzel J, Lindner T, Polei S, Hohn, A, Krause BJ, Wree A

Molecules 2018;23(3):587

 

Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity and the effect of hematological toxticity on survival

Löser A, Schwarzenböck SM, Heuschkel M, Willenberg HS, Krause BJ, Kurth J

Nucl Med Commun 2018;39(3):236-246 

 

Antifibrogenic effects of vitamin D derivatives on mouse pancreatic stellate cells

Wallbaum P, Rohde S, Lange F, Hohn A, Bergner C, Schwarzenböck SM, Krause BJ, Jaster R

World J Gastroenterol 2018;24(2):170-178

           

[18F] FDG PET/CT for assessing inguinal Lymph nodes in patients with penile cancer –correlation with histopathology after inguinal lymphadenectomy

Dräger DL, Heuschkel M, Protzel Ch, Erbersdobler, Krause BJ, Hakenberg OW, Schwarzenböck SM

Nuklearmedizin 2018;57(1):26-30

 

EANM/EARL FDG-PET/CT accreditation – summery results from the first 200 accredited imaging systems

Kaalep A, Sera T, Oyen W, Krause BJ, Chiti A, Liu Y. Boellaard R

Eur J Nucl med Mol Imaging 2017;45(3):412-422

 

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delcado Bolton RC, Gabriel M

Eur J Nucl med Mol Imaging 2018;45(5):824-845

 

2017

 

Iterative Learning Control of a Pneumatically Actuated Lung Tumour Mimic Mode

Wache A, Aschemann H, Prabel R, Kurth J, Krause BJ, Zorn S

IFAC-PapersOnLine 2017;50(1):7592-7597

Nonlinear Tracking Control of a Pneumatically Actuated Lung Tumour Mimic Model

Prabel R, Aschemann H, Kersten J, Schuenemann P, Kurth J, Krause BJ, Jonuchies I

IFAC-PapersOnLine 2016;49:71-76

 

[68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression

Schwarzenböck SM, Stenzel J, Otto T, Helldorff HV; Bergner C, Kurth J, Polei S, Lindner T, Rauer R, Hohn A, Hakenberg OW, Wester HJ, Bollmar B, Krause BJ

Oncotarget 2017;8(56):95606-95619

 

            APPswe/PS1dE9 mice with cortical amyloid pathology show a reduced NAA/Cr ratio without apparent brain atrophy: A MRS and MRI stady

            Kuhla A, Rühlmann C, Lindner T, Polei S, Hadlich S, Krause BJ, Vollmar B, Teipel SJ

            Neuroimage Clin 2017:15;581-586         

 

Application of in vivo techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer

Rohde S, Lindner T, Polei S, Stenzel J, Borufka L, Achilles S, Hartmann E, Lange F, Maletzki C, Linnebacher M, Glass Ä, Schwarzenböck SM, Kurth J, Hohn A, Vollmar B, Krause BJ, Jaster R

            Oncotarget 2017;8(41):69756-69767

 

Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin

Schmid SC, Sathe A, Guerth F, Seitz AK, Heck MM, Maurer T, Schwarzenböck S, Krause BJ, Schulz WA, Stoehr R, Gschwend JE, Retz M, Nawroth R

Urologic Oncology 2017;35(9):544.e1-544.e10

 

Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions

Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny Ch, Hofmann MS, Eiber M, Schwarzenböck S, Castellucci P, Bellisario C, Chauvie St, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A

Eur J Nucl med Mol Imaging 2017;44(10):1622-1635

 

Cardiac cell therapies fort he treatment of acute myocardial infarction: A meta-analysis from mouse studies

Lang CI, Wolfien M, Langenbach A, Müller P, Wolkenhauer O, Yavari A, Ince H, Steinhoff G, Krause BJ, David R, Glass Ä

Cell Physiol Biochem 2017;42:254-268

 

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guidline for prostate cancer imaging: version 1.0

Fendler WP, Eiber M, Behesthi M, Bomanji J, Ceci F, Cho St, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti St, Herrmann K

Eur J Nucl Med Mol Imaging 2017;44:1014-1024

 

Monitoring cytotoxicity of gemcitabine and cisplatin in T24 bladder cancer cells by the use of F-18-FDG and F-18-FMC

Rabenstein J, Fischer DC, Hakenberg OW, Jahn D, Rutz W, Hohn A, Heuschkel M, Cuber Ch, Krause BJ

Int J Clin Exp Med 2017;10(3):4556-4564

 

German multicenter study investigating 177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients

Rahbar K, Ahmadzadehfar C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarani HR, Schmidt M, Bartenstein P, Pfestroff A, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann, M, Fendler WP, Krause BJ

J Nucl Med 2017;58:85-90

 

[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy

Schwarzenböck SM, Knieling A, Souvatzoglou M, Kurth J, Steiger K, Eiber M, Esposito I, Retz M, Kübler H, Gschwend JE, Schwaiger M, Krause BJ, Thalgott M

Oncotarget 2017;7(39):63747-63757

 

2016

 

Evaluation of prostate cancer with 11C- and 18F-Choline PET/CT: Diagnosis and initial staging

Nitsch S, Hakenberg OW, Heuschkel M, Dräger D, Hildebrandt G, Krause BJ, Schwarzenböck SM

J Nucl Med 2016;57(Suppl 3):38S-42S

 

Radionuklidtherapie von Knochenmetastasen mittels Radium-223; S1 Leitlinie

Pöppel, TD, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Mitterhauser M, Scheidhauer K, Schenck M, Sonnenschein W, Gabriel M

Nuklearmedizin 2016;55(5):177-186

 

Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate Cancer

Schwarzenböck SM, Eiber M, Kundt G, Retz M, Sakretz M, Kurth J, Treiber U, Nawroth R, Rummeny EJ, Gschwend JE, Schwaiger M, Thalgott M, Krause BJ

Eur J Nucl Med Mol Imaging 2016;43(12):2105-2113

 

The 2015 Revised American Thyreoid Association guidlines for the management of medullary thyreoid carcinoma: the „evidence-based“ refusal to endorse them by EANM due to „not evidence-based“ marginalization oft he role of Nuclear Medicine

Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ, Langsteger W, Verburg FA, Luster M

Eur J Nucl Med Mol Imaging 2016;43:1486-1490

 

Beta-Amyloid-PET-Bildgebung des Gehirns

Barthel H, Meyer PT, Drzezga A, Bartenstein P, Boecker H, Brust P, Buchert R, Coenen HH, la Fougére C, Gründer G, Grünwald F, Krause BJ, Kuwert T, Schreckenberger M, Tatsch K, Langen K-J, Sabri O

Nuklearmedizin 2016;55(4):129-137

 

Therapie mit 177Lu-PSMA-617 – Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom

Fendler WP, Kratochwill C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heizel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ

Nuklearmedizin 2016;55(3):123-128

 

Increased choline uptake in macrophages and prostate cancer cells does not allow for differentiation between benign and malignant prostate pathologies

Schwarz T, Seidl C, Schiemann M, Senekowitsch-Schmidtke R, Krause BJ

Nuclear Medicine and Biology 2016;43:355-359  

 

Non-invasive assessment of inter- and intrapatient variability of integrin expression in metastasized prostate cancer by PET

Beer AJ, Schwarzenböck S, Zantl N, Sovatzoglou M, Maurer T, Watzlowik P, Kessler H, Wester HJ, Schwaiger M, Krause BJ

Oncotarget 2016;7(19)28151-28159

 

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasm in Germany: A multi-institutional registry study with prospective follow-up

Hörsch D, Ezzidin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, Schreckenberger M, Krause BJ, Bengel FM, Bartenstein P, Biersack HJ, Pöpperl G, Baum RP

Eur J Cancer 2016;58:41-51

 

18F-fluoroethyl-l-thyrosine (FET) PET to delineate tumor residuals after glioblastoma resection: A comparison to standard postoperative MRI

Buchmann N, Kläsner B, Gempt J, Bauer JS, Pyka T, Delbridge C, Meyer B, Krause BJ, Ringel F

World Neurosurg. 2016;89:420-426

Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer

Verburg FA, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ, Langsteger W, Luster M; EANM and the EANM Thyroid Committee.

Eur J Nucl Med Mol Imaging 2016;43(6):1001-1005

 

PET/CT with 11 C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta analysis and critical review of available data

Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ, Oyen W, Chiti A

Eur J Nucl Med Mol Imaging 2016;43:55-69

 

CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1

Sathe A, Koshy N, Schmid SC, Thalgott M, Schwarzenböck SM, Krause BJ, Holm PS, Gschwend JE, Retz M, Nawroth R

J Urol 2016;195:771-779

 

Cardiac FDG-PET: a straight forward tool with high potential

Lang CI, Krause BJ, David R

Eur Heart J Cardiovasc Imaging 2016;17:130-131

 

Comparison of [11C]Choline ([ 11C]CHO) and [18F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model

Schwarzenböck SM, Schmeja P, Kurth J, Souvatzoglou M, Nawroth R, Treiber U, Kundt G, Berndt S, Graham K, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Dinkelborg L, Wester HJ, Krause BJ

Mol Imaging Biol 2016;18(3):393-401

 

2015

 

Die Cholin PET/CT für Diagnostik, Staging und Restaging des Prostatakarzinoms

Heuschkel M, Krause BJ, Hakenberg OW, Schwarzenböck SM

Der Nuklearmediziner 2015:38(2):109-118

 

The relative importance of imaging markers fort he prediction of Alzheimer´s disease in mild cognitive impairmend – Beyond classical regression

Teipel SJ, Kurth J, Krause BJ, Grothe MJ

Neuroimage Clin 2015;8:583-593

 

18F-NaF PET/CT: EANM procedure guidlines for bone imaging

Beheshti M, Mottaghy FM, Payche F, Behrendt FFF, Van den Wyngaert T, Fogelmann I, Strobel K, Celli M, Fanti S, Giammarile F, Krause BJ, Langsteger W

Eur J Nucl Med Mol Imaging 2015:42;1767-1777

 

Early [18F]FET-PET in Gliomas after surgical resection: Comparison with MRI and histopathologie

Kläsner B, Buchmann N, Gempt J, Ringel F, Lapa C, Krause BJ

PLOS one 2015:26;10(10):e0141153

 

124I-PET Assessment of human sodium iodide symporter reporter gene activity for highly sensitive in vivo monitoring of teratoma formation in mice

Lehner S, Lang C, Kaissis G, Todica A, Zacher MJ, Boening G, Spitzweg C, Herbach N, Franz WM, Krause BJ, Steinhoff G, Bartenstein P, Hacker M, David R

Mol Imaging Biol 2015;17(6):874-883

 

Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

Thalgott M, Rack B, Eiber M, Souvatzoglou M, Heck MM, Kronester C, Andergassen U, Kehl V, Krause BJ, Gschwend JE, Retz M, Nawroth R

BMC Cancer 2015;15:458

 

Wie schreibe ich eine gute Übersichtsarbeit?

Krause BJ, Khan C, Antoch G

Nuklearmedizin 2015;54(2):69-74

 

Robust, fully automatic delineation of the head contout by sterotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy

Lange C, Kurth J, Seese A, Schwarzenböck S, Steinhoff K, Umland-Seidler B, Krause BJ,

Brenner W, Sabri O, Hesse S, Buchert R

Eur Rad 2015 ;25:2709-2717

 

Circulating tumor cells versus objective response assessment predicting survival in metastastic castration-resistant prostate cancer patients treated with docetaxel chemotherapy

Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M, Gschwend JE, Andergassen U, Nawroth R

J Cancer Res Clin Oncol 2015;141(8):1457-1464

 

Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor-exprimierender Tumore

DGN Leitlinie (S1)        

Poeppel TD, Boy C, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Krause BJ, Schmidt D, Amthauer H, Rösch F, Nagarajah, Führer D, Lahner H, Pöpperl G, Hörsch D, Walter MA, Baum RP

Nuklearmedizin 2015;54(1):1-11

 

Positronenemissionstomographie 2013 in Deutschland

Kotzerke J, Oehme L, Grosse J, Hellwig D, Arbeitsausschuss PET der DGN u. a. Krause BJ

Nuklearmedizin 2015;54(2):53-59

 

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ.

Eur J Nucl Med Mol Imaging 2015;42(2):328-354

 

Comparison of [11C]Choline ([ 11C]CHO) and S(+)-β-Methyl-[11C]Choline ([ 11C]SMC) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model

Schwarzenböck SM, Gertz J, Souvatzoglou M, Kurth J, Sachs D, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester HJ, Krause BJ

Mol Imaging Biol 2015;17(2):248-256

 

Prediction of Parkinson´s disease subsequent to severe depression: a ten-year follow-up study

Walter U, Heilmann R, Kaulitz L, Just T, Krause BJ, Benecke R, Höppner J

J neural Transm 2015;122(6):789-797

 

Repetitive transcranial magnetic stimulation (rTMS) in schizophrenia with treatment-refractoty auditory hallucinations and major self-mutilation

Schulz T, Berger Ch, Krecklow B, Kurt J, Schwarzenboeck S, Foley P, Thome J, Krause BJ, Hoeppner J

J Neural Transm 2015;122(S1):  19-23

 

2014

 

Alzheimer – Frühere Diagnostik dank neuer Bildgebungstechniken

Kurth J, Kasper E, Teipel S, Krause BJ

DZKF 2014;14-19

 

CT-based attenuation correction in I-123-Ioflupane SPECT

Lange C, Seese A, Schwarzenböck S, Steinhoff K, Umland-Seidler B, Krause BJ, Brenner W, Sabri O, Kurth J, Hesse S, Buchert R

PLOS one 2014;9(9):e108238

 

Welche bildgebenden Verfahren sind in der Demenz-Diagnostik sinnvoll?

Sakretz M, Kurth J, Teipel S, Krause BJ

DNP-Der Neurologe&Psychiater 2014;15(10)

11C-Choline PET/ pathology image coregistration in primary localized prostate cancer

Grosu AL, Weirich G, Wendl C, Prokic V, Kirste S, Geinitz H, Souvatzoglou M, Gschwend JE, Schwaiger M, Molls M, Weber WA, Treiber U, Krause BJ

Eur J Nucl Med Mol Imaging 2014;41(12):2242-2248

 

In-vivo of the acute retention of stem cell derivatives and fribroblasts after intramyocardial transplantation

Lang, C, Lehner S, Todica A, Boening G, Zachert M, Franz WM, Krause BJ, Bartenstein P,

Hacker M, David R

Eur J Nucl Med Mol Imaging 2014;41(12):2325-2336

 

Ösophagus- und Magenkarzinom – Staging und Bildgebung

Schwarzenböck S, Krause BJ, Ebert M, Grenacher L

Klinikarzt 2014;43:348-353

 

Prognostic Value of 11C-Choline PET/CT and CT for Predicting Survival of Bladder

Cancer Patients Treated with Radical Cytectomy

Mauerer T, Horn T, Souvatzoglou M, Eiber M, Beer AJ, Heck MM, Haller B, Gschwend JE,

Schwaiger M, Treiber U, Krause BJ

Urol Int 2014;93(2):207-213

 

Preoperative lymph node Staging in patients with primary prostate cancer: Comparison and correlation of quantitative imaging parameters in diffusion weighted imaging [11C]-choline PET/CT

Vag T, Heck M, Beer AJ, Souvatzoglou M, Weirich G, Holzapfel K, Krause BJ, Schwaiger M, Eiber M

Eur Radiol 2014;24(8):1821-1826

 

Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells

Elsner A, Lange F, Fitzner B, Heuschkel M, Krause BJ, Jaster R

World J of Gastro2014;20(24):7914-7925

 

Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C] choline positron emission tomography/ computed tomography for preoperative lymph node staging in prostate cancer patients

Heck M, Souvatzoglou M, Retz M, Nawroth R, Kübler H, Maurer T, Thalgott M, Gramer BM, Weirich G, Rondak IC, Rummeny EJ, Schwaiger M, Gschwend JE, Krause BJ, Eiber M

Eur J Med Mol Imaging 2014;41:694-701

 

Cholinergic basal forebrain atrophy predicts amyloidburden in Alzheimer`s disease

Teipel S, Heinsen H, Amaro Jr. E, Grinberg LT, Krause BJ, Grothe M, fort he Alzheimer`s Disease Neuroimaging Initiative

Neurobiology of Aging 2014;35:482-491

 

European Association of Nuclear medicine: adapt the present, shape the future

Frangos S, Knapp W, - on behalf of the EANM Executive Committee (Krause BJ)

Eur J Nucl Med Mol Imaging 2014;41:590-591

 

Quality criteria for multidisciplinary oncology guidelines – the ECCO multidisciplinary clinical guidlines forum

Schrijvers D, van den Velde C, Bregni M, Caraceni A, Cardoso F, Erdem S, Geldenborn H, Grisold W, Honore PGH, Krause BJ, Licitra L, Mansel R, Margilies H, Parsons K, Poston G, Valentini V, Zola P

Eur Assoc Neurooncol Mag 2014;4(1):6-8

 

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Thalgott M, Horn T, Heck M, Maurer T, Eiber M, Retz M, Autenrieth M, Herkommer K, Krause BJ, Gschwend JE, Treiber U, Kübler HR

J of Hema & Oncol 2014;7:20

 

Molekulare multimodale Hybridbildgebung des Prostata- und Blasenkarzinoms

Maurer T, Eiber M, Krause BJ   

Der Urologe 2014;53:469-483

Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects

Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ, für the Alzheimer´s Disease Neuroimaging Initiative

Alzheimer`s & Dementia 2014:10:S344-S353

 

2013

 

Perfusion brain imaging with SPECT-technique. German Guidline S1

Kranert T, Menzel C, Bartenstein P, Brust P, Coenen HH, Krause BJ, Kuwert T, Sabri O, Schreckenberger M, Tatch K, Grünwald F

Nuklearmedizin 2013;52(5):157-162

 

Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates

Krause BJ, Souvatzoglou M, Treiber U.

Urol Oncol 2013 May;31(4):427-435

 

Biodistribution and radiation dosimetry in healthy volunteers of a novel tumour-specific probe for PET/CT imaging: BAY 85-8050

Smolarz K, Krause BJ, Graner FP, Wagner FM, Wester HJ, Sell T, Bacher-Stier C, Fels L, Dinkelborg L, Schwaiger M.

Eur J Nucl Med Mol Imaging 2013;40(12):1861-1868

 

[11C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model

Schwarzenböck S, Sachs D, Souvatzoglou M, Schuster T, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler S, Schwaiger M, Senekowitsch-Schmidtke R, Krause BJ.

Nuklearmedizin 2013 Aug 8;52(4):141-147

 

Molecular imaging of dementia

Kurth J, Sakretz M, Teipel S, Krause BJ

Geriatric Mental Health Care 2013;1(3):56-62

 

Das Peniskarzinom

Protzel C, Kakies C, Schwarzenböck S, Kuhnt T, Ebersdobler A, Krause BJ, Hakenberg OW

Der Onkologe 2013;19(2):149-162

 

Molecular imaging techniques in the diagnosis of dementia

Kurt J, Kilimann I, Krause BJ, Teipel S

Nervenheilkunde2013;32:725-732

 

Tumour volume delineation in prostate cancer assessed by (11C)choline PET/C/: validation with surgical specimens

Bundschuh RA, Wendl CM, Weirich G, Eiber M, Sovatzoglou M, Treiber U, Küberler H, Maurer T, Gschwend JE, Geinitz H, Grosu AL, Ziegler SI, Krause BJ

Eur J Nucl Med Mol Imaging 2013;40(6):824-831

 

Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer

Schwarzenböck S, Kurth J, Gocke C, Kuhnt T, Hildebrandt G, Krause BJ

Eur J Nucl Med Mol Imaging 2013;40(Suppl 1):28-35

 

(S)-4-(3-18F-Fluoropropyl)-L-Glutamic Acid: An 18F-Labaled Tumor-Specific Probe for PET/CT Imaging-Dosimetry

Smolarz K, Krause BJ, Graner FP, Wagner FM, Hultsch C, Bacher-Stier C, Sparka RB, Ramsay S, Fels LM, Nunkelborg LM, Schwaiger M

J Nucl Med 2013;54(6):861-866

 

2012

 

S3-guidline-diagnosis and treatment of gastric carcinoma:relevance for radiologic imaging

Grenacher L, Schwarz M, Lordick F, Krause BJ, Roecken C, Moening S, Ebert M, Jenssen C, Kauczor HU, Moehler M, Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)

Rofo 2012;184(8):706-12                                                          

PET/CT and choline: diagnosis and staging

Farsad M, Schwarzenböck S, Krause BJ

Q J Nucl Med Mol Imaging 2012;56(4):343-353

 

SNM/EANM Guidline for Guideline Development 6.0

Delbeke D, Chiti A, Christian P, Darcourt J, Donohoe K, Flotats, Krause BJ, Royal HD,

J Nucl Med Technol 2012;40:283-289

                                                                      

18F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions

Buck D, Förschler A, Lapa C, Schuster T, Vollmar P, Korn T, Nessler S, Stadelmann C, Drzezga A, Buck AK, Wester HJ, Zimmer C, Hemmer B, Krause BJ

J Nucl Med 2012;53(8):1269-1276

 

Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy

Maurer T, Souvatzoglou M, Kübler H, Opercan K, Schmidt S, Herrmann K, Stollfuss J, Weirich G, Haller B, Gschwend JE, Schwaiger M, Krause BJ, Treiber U

Eur Urol 2012;61(5):1031-1038

 

Choline PET and PET/CT in primary diagnosis and staging of prostate cancer

Schwarzenböck S, Souvatzoglou M, Krause BJ

Theranostics 2012;2(3):318-330                   

                                                                 

Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients with Lymph Node Metastases

Fortuin AS, Daserno WMLLG, Meijer HJM, Jager GJ, Takahashi S, Debats OA, Reske SN, Schick C, Krause BJ, van Oort I, Witjes AJ, Hoogeveen YL, van Lin ENJ, Baretsz JO

Int J Radiation Oncol Biol Phys 2012;84(3):712-718

 

2011

 

Letter to the Editor:  Re: Mottet N, Bellmunt J, Bolla M, et all: EAU Guidelines on prostate Cancer Part II: Treatment of advanced, relapsing and gastration-resistant prostate Caner

Eur Urol 2011;60:e37-e38                                 

 

PET/CT for the diagnosis, staging and restaging of prostate cancer

Souvatzoglou M, Gärtner F, Schwarzenböck S, Beer AJ, Schwaiger M, Krause BJ

Imaging in Medicine 2011;3(5):571-585                         

 

Welche neuen PET-Tracer braucht die Strahlentherapie?

Schwarzenböck S, Herrmann K, Gärtner F, Kläsner B, Souvatzoglou M, Krause BJ

Der Nuklearmediziner 2011;34(2);99-108

 

18F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can do

Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czemin J.

Q J Nucl Med Mol Imaging 2011;55(6):620-632

 

S6K1 and 4E-BP1 are independent regulated and control cellular growth in Bladder cancer

Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE, Retz M

PLoS One 2011;6(11):e27509 

 

Prognistic value of (18F)-Flurop-Deoxy-Glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma

Essler M, Link A, Belloni B, Mirceva V, Souvatzoglou M, Thaler M, Haller B, Hein R, Krause BJ

PloS One 2011;6(9):e24632

 

Curative treatment of oesophageal carcinoma: current options and future developments

Wolf MC, Stahl M, Krause BJ, Bonavina C, Bruns C, Belka C, Zehentmayr F

Radiat Oncol 2011;6:55

Molecular imaging of proliferation and glucose utilization: utility for monotoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer

Ott K, Hermann K, Schuster T, Lange R, Becker K, Wieder HA, Wester HJ, Siewert JR, Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Pechel C, Schwaiger M, Lordick F, Krause BJ

Ann Surg Oncol 2011;18(12):3316-3323

 

Positron emission tomography – current role in the diagnostic and treatment of upper gastrointestinal carcinomas

Lordick F, Ott K, Krause BJ

Dtsch. Med. Wochenschr 2011;136(20):1061-1066

 

German S3-guidline "Diagnosis and treatment of esophagogastric cancer"

Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C; AWMF; AWMF.

Z Gastroenterol. 2011;49(4):461-531

 

The sensitivity of (11)Choline PET/CT to localize prostate cancer depends on the tumor configuration

Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, Eiber M, Herrmann K, Kuebler H, Wester HJ, Hoefler H, Gschwend J, Schwaiger M, Treiber U, Krause BJ

Clin Cancer Res 2011;17(11):3751-3759        

         

Infuence of (11)Choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochjemical recurrence of prostate cancer

Souvatzoglou M, Krause BJ, Pürschel A, Thamm R, Schuster T, Buck AK, Zimmermann F, Molis M, Schwaiger M, Geinitz H

Radiother Onco 2011;99(2):193-200

 

18F-FDG-PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the municon II trial

Meyer zum Büschenfelde C, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ

J Nucl Med 2011;52(8):1189-1196

 

German Guidelines for brain-tumor imaging by PET and SPECT using labeled amino acids

Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A, Grünwald F, Krause BJ, Kuwert T, Sabri O, Tatsch K, Weber WA, Schreckenberger M

Nuklearmedizin 2011;50(4):167-173

 

Radionuclide and Hybrid Imaging of Recurrent Prostate Cancer

Beer A, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ

Lancet Oncology 2011;12(2):181-191

 

The Role of choline positron emission tomography/computed tomography in the management of patients with prostatate-specific antigen progression after radical treatment of prostate cancer

Picchio M, Briganti A ,Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN

Eur Urology 2011;59(1):51-60

 

Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11C-Choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer

Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, Maurer T, Kübler H, Wester HJ, Gaa J, Krause BJ

Mol Imag Biol  2011;13(2):352-361

 

Comparison of different SUV-based methods for prediction of response to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI

Herrmann K, Bundschuh RA, Rosenberg R, Schmidt S, Praus C, Souvatzoglou M, Becker K, Schuster T, Essler M, Wieder HA, Friess H, Ziegler SI, Schwaiger M, Krause BJ

Mol Imag Biol 2011;13(5):1011-1

Nach oben